Lakefront Biotherapeutics (GLPGF) Debt Ratio (2020)
Lakefront Biotherapeutics' (GLPGF) quarterly Debt Ratio came in at 0.0 in Q4 2020.
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Debt Ratio (2020) Analysis & Trends
Lakefront Biotherapeutics (GLPGF) has reported Debt Ratio for 1 consecutive years, with 0.0 the latest figure, recorded in Q4 2020.
- On a quarterly basis, Debt Ratio changed N/A year-over-year to 0.0 in Q4 2020; TTM through Dec 2020 was 0.0, a N/A change from a year earlier, with the FY2020 full-year figure at 0.0, changed N/A from the prior year.
- Debt Ratio was 0.0 for Q4 2020 at Lakefront Biotherapeutics.
- Over five years, Debt Ratio peaked at 0.0 in Q4 2020 and troughed at 0.0 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.51 Bn | 197.52 Bn | 7.24 Bn | 0.66 |
| 2 | Gilead Sciences | 181.48 Bn | 178.30 Bn | 6.22 Bn | 0.58 |
| 3 | Vertex Pharmaceuticals | 132.45 Bn | 124.60 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn | 0.05 |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.72 Bn | 49.59 Bn | 52.00 Mn | 0.05 |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | 0.25 |
| 9 | Roivant Sciences | 30.31 Bn | 30.31 Bn | 1.16 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | - |